Secukinumab

Secukinumab (AIN457) is a high affinity, human monoclonal antibody targeted against interleukin (IL)-17A. Secukinumab is the first-in-class anti-IL-17 agent used for the research of plaque psoriasis, ankylosing spondylitis and psoriatic arthritis[1][2].

Human IgG1/κ monoclonal antibody:
Treatment of moderate to severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis

Potentially hazardous interactions with other drugs
Vaccines: risk of generalised infections with live vaccines - avoid.

IL-17A

The majority of IgG elimination occurs via intracellular catabolism, following fluid-phase or receptor mediated endocytosis.

[1] Shirley M, et al. Secukinumab: A Review in Psoriatic Arthritis. Drugs. 2016;76(11):1135-1145. DOI:10.1007/s40265-016-0602-3
[2] Reich K, et al. Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study. Br J Dermatol. 2020;182(2):304-315. DOI:10.1007/s40265-016-0602-3
[3] Elain G, et al. The selective anti-IL17A monoclonal antibody secukinumab (AIN457) attenuates IL17A-induced levels of IL6 in human astrocytes. Glia. 2014;62(5):725-735. DOI:10.1002/glia.22637